{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:37:24Z","timestamp":1762321044740,"version":"build-2065373602"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Ophthalmol."],"abstract":"<jats:p>Autosomal dominant optic atrophy (ADOA) is among the most prevalent inherited optic neuropathies with hallmark symptoms of bilateral, painless, progressive, and typically permanent vision loss over time. ADOA can affect patients\u2019 quality of life with debilitating visual symptoms, and there is a pressing need for effective therapeutics. In this paper, we review the current and future investigational therapies for ADOA, including the use of intravitreal injections of antisense oligonucleotides through Targeted Augmentation of Nuclear Gene Output (TANGO), CRISPR-based therapy, genetic editing, gene replacement approaches, and idebenone, a small-molecule mitochondrial modulator. Additionally, we review clinical trials for ADOA treatment and opportunities for future research on ADOA therapeutics, including the utilization of mitochondria-targeted peptides and antioxidants, NAD+ boosters\/metabolic support, mitophagy and fission-fusion modulators, and cell-based regenerative therapy. The use of emerging technology to compensate for OPA1 protein haploinsufficiency provides new and vast avenues for the management of this otherwise vision-altering disease. Increased awareness of therapeutics for ADOA will allow for patient counseling regarding treatment access via clinical trials and for underscoring the importance of genetically testing family members, who may be incidentally identified with ADOA in a timely manner for newly available therapies. While patients with ADOA typically have poor visual prognoses, there are increasing promising therapies with the potential for preserving and improving visual function.<\/jats:p>","DOI":"10.3389\/fopht.2025.1688232","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:22:28Z","timestamp":1762320148000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["IT TAKES TWO TO TANGO: potential novel therapies for autosomal dominant optic atrophy"],"prefix":"10.3389","volume":"5","author":[{"given":"Ritu","family":"Sampige","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyra E.A.","family":"Seaborn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly","family":"Pluenneke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"Jyothi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Saland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisom M.","family":"Chinedu-Obi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Keehn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew G.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1750-1172-7-46","article-title":"Dominant optic atrophy","volume":"7","author":"Lenaers","year":"2012","journal-title":"Orphanet J Rare Diseases"},{"key":"B2","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ajo.2006.12.038","article-title":"Autosomal dominant optic atrophy: penetrance and expressivity in patients with OPA1 mutations","volume":"143","author":"Cohn","year":"2007","journal-title":"Am J Ophthalmology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3109\/08820538.2013.825296","article-title":"Autosomal dominant hereditary optic neuropathy (ADOA): A review of the genetics and clinical manifestations of ADOA and ADOA +","volume":"28","author":"Skidd","year":"2013","journal-title":"Semin Ophthalmol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.134726","article-title":"The natural history of OPA1-related autosomal dominant optic atrophy","volume":"92","author":"Cohn","year":"2008","journal-title":"Br J Ophthalmology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000001830","article-title":"OPA1 dominant optic atrophy: pathogenesis and therapeutic targets","volume":"43","author":"Wong","year":"2023","journal-title":"J Neuro-Ophthalmology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-1261","article-title":"OPA1, the disease gene for autosomal dominant optic atrophy, is specifically expressed in ganglion cells and intrinsic neurons of the retina","volume":"45","author":"Pesch","year":"2004","journal-title":"Invest Ophthalmol Visual Science"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.mito.2018.07.006","article-title":"Meta-analysis of genotype-phenotype analysis of OPA1 mutations in autosomal dominant optic atrophy","volume":"46","author":"Ham","year":"2019","journal-title":"Mitochondrion"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2009.04.012","article-title":"OPA1-associated disorders: Phenotypes and pathophysiology","volume":"41","author":"Amati-Bonneau","year":"2009","journal-title":"Int J Biochem Cell Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2005.034892","article-title":"Autosomal dominant optic atrophy associated with hearing impairment and impaired glucose regulation caused by a missense mutation in the WFS1 gene","volume":"43","author":"Eiberg","year":"2006","journal-title":"J Med Genet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/bjo.87.1.48","article-title":"Optic disc morphology of patients with OPA1 autosomal dominant optic atrophy","volume":"87","author":"Votruba","year":"2003","journal-title":"Br J Ophthalmology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2011.12.002","article-title":"Optic atrophy plus phenotype due to mutations in the OPA1 gene: two more Italian families","volume":"315","author":"Ranieri","year":"2012","journal-title":"J Neurol Sci"},{"key":"B12","first-page":"2755","article-title":"Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for the treatment of autosomal dominant optic atrophy","volume":"61","author":"Venkatesh","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/antiox7120186","article-title":"Mitochondrial membrane dynamics-functional positioning of OPA1","volume":"7","author":"Lee","year":"2018","journal-title":"Antioxidants (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s12886-022-02546-0","article-title":"Autosomal dominant optic atrophy caused by six novel pathogenic OPA1 variants and genotype-phenotype correlation analysis","volume":"22","author":"Han","year":"2022","journal-title":"BMC Ophthalmol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e2207471120","DOI":"10.1073\/pnas.2207471120","article-title":"OPA1 disease-causing mutants have domain-specific effects on mitochondrial ultrastructure and fusion","volume":"120","author":"Cartes-Saavedra","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B16","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1186\/s12967-025-06471-w","article-title":"OPA1 mutations in dominant optic atrophy: domain-specific defects in mitochondrial fusion and apoptotic regulation","volume":"23","author":"Zhang","year":"2025","journal-title":"J Transl Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.305","article-title":"Loss of functional OPA1 unbalances redox state: implications in dominant optic atrophy pathogenesis","volume":"3","author":"Millet","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"B18","article-title":"Antisense oligonucleotide mediated increase in OPA1 improves mitochondrial function in fibroblasts derived from patients with autosomal dominant optic atrophy (ADOA)","author":"Venkatesh","year":"2021","journal-title":"Assoc Res Vision Ophthalmology: Stoke Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13149","article-title":"Autophagy controls the pathogenicity of OPA1 mutations in dominant optic atrophy","volume":"21","author":"Kane","year":"2017","journal-title":"J Cell Mol Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41420-025-02442-8","article-title":"Contrasting pathophysiological mechanisms of OPA1 mutations in autosomal dominant optic atrophy","volume":"11","author":"Yao","year":"2025","journal-title":"Cell Death Discovery"},{"key":"B21","first-page":"1482","article-title":"Antisense oligonucleotide mediated increase in OPA1 improves mitochondrial function in fibroblasts derived from patients with autosomal dominant optic atrophy (ADOA)","volume":"62","author":"Venkatesh","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B22","volume-title":"Stoke Therapeutics Receives Authorization to Initiate a Phase 1\/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom","year":"2023"},{"key":"B23","first-page":"1111","article-title":"STK-002, an antisense oligonucleotide (ASO) for the treatment of autosomal dominant optic atrophy (ADOA), is taken up by retinal ganglion cells (RGC) and upregulates OPA-1 protein expression after intravitreal administration to non-human primates (NHPs)","volume":"63","author":"Anderson","year":"2022","journal-title":"Invest Ophthalmol Visual Science"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2024.0022","article-title":"Antisense oligonucleotide STK-002 increases OPA1 in retina and improves mitochondrial function in autosomal dominant optic atrophy cells","volume":"34","author":"Venkatesh","year":"2024","journal-title":"Nucleic Acid Ther"},{"key":"B25","first-page":"88","article-title":"OSPREY: an open-label study to investigate safety, tolerability, and exposure of the antisense oligonucleotide (ASO) STK-002 in patients with autosomal dominant optic atrophy (ADOA)","volume":"65","author":"Votruba","year":"2024","journal-title":"Invest Ophthalmol Visual Science"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6364","DOI":"10.3390\/ijms26136364","article-title":"CRISPRa-mediated increase of OPA1 expression in dominant optic atrophy","volume":"26","author":"Becchi","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI158287","article-title":"CRISPR\/Cas therapeutic strategies for autosomal dominant disorders","volume":"132","author":"Caruso","year":"2022","journal-title":"J Clin Invest"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16771","article-title":"Therapeutic applications of CRISPR\/Cas9 gene editing technology for the treatment of ocular diseases","volume":"290","author":"Sundaresan","year":"2023","journal-title":"FEBS J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2020.06.011","article-title":"Ocular delivery of CRISPR\/Cas genome editing components for treatment of eye diseases","volume":"168","author":"Yu","year":"2021","journal-title":"Adv Drug Delivery Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000000570","article-title":"International consensus statement on the clinical and therapeutic management of leber hereditary optic neuropathy","volume":"37","author":"Carelli","year":"2017","journal-title":"J Neuro-Ophthalmology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"102346","DOI":"10.1016\/j.ajoc.2025.102346","article-title":"The crossroads of Leber hereditary optic neuropathy and autosomal dominant optic Atrophy: Clinical profiles of patients with coexisting pathogenic genetic variants","volume":"38","author":"Halawani","year":"2025","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51026","article-title":"Idebenone increases chance of stabilization\/recovery of visual acuity in OPA1-dominant optic atrophy","volume":"7","author":"Romagnoli","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042242","article-title":"Rare primary mitochondrial DNA mutations and probable synergistic variants in leber\u2019s hereditary optic neuropathy","volume":"7","author":"Achilli","year":"2012","journal-title":"PloS One"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2174\/092986709787846578","article-title":"Mitochondrial respiratory complex I: structure, function and implication in human diseases","volume":"16","author":"Sharma","year":"2009","journal-title":"Curr Med Chem"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2019.11.030","article-title":"The ying and yang of idebenone: Not too little, not too much \u2013 cell death in NQO1 deficient cells and the mouse retina","volume":"152","author":"Varricchio","year":"2020","journal-title":"Free Radical Biol Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/0014-5793(85)80650-5","article-title":"Stimulation of the respiratory and phosphorylating activities in rat brain mitochondria by idebenone (CV-2619), a new agent improving cerebral metabolism","volume":"184","author":"Sugiyama","year":"1985","journal-title":"FEBS Letters"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2015.01.009","article-title":"Border between natural product and drug: Comparison of the related benzoquinones idebenone and coenzyme Q10","volume":"4","author":"Gueven","year":"2015","journal-title":"Redox Biol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.preteyeres.2010.11.002","article-title":"Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies","volume":"30","author":"Yu-Wai-Man","year":"2011","journal-title":"Prog Retin Eye Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065072","article-title":"The role of citicoline and coenzyme Q10 in retinal pathology","volume":"24","author":"Garc\u00eda-L\u00f3pez","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12112011","article-title":"Targeting mitochondrial dysfunction and oxidative stress to prevent the neurodegeneration of retinal ganglion cells","volume":"12","author":"Catalani","year":"2023","journal-title":"Antioxidants (Basel)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2741\/4231","article-title":"Clinical applications of coenzyme Q10","volume":"19","author":"Garrido-Maraver","year":"2014","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbabio.2011.10.012","article-title":"The effects of idebenone on mitochondrial bioenergetics","volume":"1817","author":"Giorgio","year":"2012","journal-title":"Biochim Biophys Acta (BBA) - Bioenergetics"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2022.58.11.3448291","article-title":"Current treatment options for treating OPA1-mutant dominant optic atrophy","volume":"58","author":"Ferro Desideri","year":"2022","journal-title":"Drugs Today (Barc)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/genes15121559","article-title":"Insights on the genetic and phenotypic complexities of optic neuropathies","volume":"15","author":"D\u2019Esposito","year":"2024","journal-title":"Genes (Basel)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)91442-B","article-title":"Remission of Leber\u2019s hereditary optic neuropathy with idebenone","volume":"340","author":"Mashima","year":"1992","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000001023","article-title":"Real-world clinical experience with idebenone in the treatment of leber hereditary\u00a0optic neuropathy","volume":"40","author":"Catarino","year":"2020","journal-title":"J Neuro-Ophthalmology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"101437","DOI":"10.1016\/j.xcrm.2024.101437","article-title":"Therapeutic benefit of idebenone in patients with Leber hereditary optic neuropathy: The LEROS nonrandomized controlled trial","volume":"5","author":"Yu-Wai-Man","year":"2024","journal-title":"Cell Rep Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1080\/01658107.2023.2251575","article-title":"Idebenone treatment in patients with OPA1-dominant optic atrophy: A prospective phase 2 trial","volume":"47","author":"Valentin","year":"2023","journal-title":"Neuroophthalmology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awr170","article-title":"A randomized placebo-controlled trial of idebenone in Leber\u2019s hereditary optic neuropathy","volume":"134","author":"Klopstock","year":"2011","journal-title":"Brain"},{"key":"B50","first-page":"5305","article-title":"PYC-001: A promising RNA therapeutic for autosomal dominant optic atrophy","volume":"65","author":"Grainok","year":"2024","journal-title":"Invest Ophthalmol Visual Science"},{"key":"B51","unstructured":"Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy: MedPath"},{"key":"B52","unstructured":"Neurophth"},{"key":"B53","doi-asserted-by":"publisher","first-page":"41","DOI":"10.21037\/sci.2019.11.01","article-title":"Stem Cell Ophthalmology Treatment Study (SCOTS): bone marrow derived stem cells in the treatment of Dominant Optic Atrophy","volume":"6","author":"Weiss","year":"2019","journal-title":"Stem Cell Investig"},{"key":"B54","volume-title":"Stem Cell Ophthalmology Treatment Study II (SCOTS2)","year":""},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.20950","article-title":"Effects of OPA1 mutations on mitochondrial morphology and apoptosis: relevance to ADOA pathogenesis","volume":"211","author":"Olichon","year":"2007","journal-title":"J Cell Physiol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1186\/s12967-022-03685-0","article-title":"Current advances in gene therapy of mitochondrial diseases","volume":"20","author":"Soldatov","year":"2022","journal-title":"J Trans Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/biom15030433","article-title":"The balance of MFN2 and OPA1 in mitochondrial dynamics, cellular homeostasis, and disease","volume":"15","author":"Zanfardino","year":"2025","journal-title":"Biomolecules"},{"key":"B58","first-page":"5862","article-title":"Flavoprotein fluorescence in the 24-month FALCON natural history study of autosomal dominant optic atrophy: A potential biomarker for mitochondrial dysfunction","volume":"66","author":"Votruba","year":"2025","journal-title":"Invest Ophthalmol Visual Science"},{"key":"B59","volume-title":"Stoke Therapeutics Second Quarter 2025 Business Update","year":""},{"key":"B60","volume-title":"Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates","year":"2025"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.18632\/aging.101231","article-title":"Mitochondrial replacement in an iPSC model of Leber\u2019s hereditary optic neuropathy","volume":"9","author":"Wong","year":"2017","journal-title":"Aging (Albany NY)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-024-01125-5","article-title":"Mitochondria transfer-based therapies reduce the morbidity and mortality of Leigh syndrome","volume":"6","author":"Nakai","year":"2024","journal-title":"Nat Metab"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddae008","article-title":"OPA1 mutation affects autophagy and triggers senescence in autosomal dominant optic atrophy plus fibroblasts","volume":"33","author":"Zanfardino","year":"2024","journal-title":"Hum Mol Genet"},{"key":"B64","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1038\/s41467-020-17821-1","article-title":"Inhibition of autophagy curtails visual loss in a model of autosomal dominant optic atrophy","volume":"11","author":"Zaninello","year":"2020","journal-title":"Nat Commun"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1172\/JCI191315","article-title":"SARM1 loss protects retinal ganglion cells in a mouse model of autosomal dominant optic atrophy","volume":"135","author":"Ding","year":"2025","journal-title":". J Clin Invest"},{"key":"B66","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1084\/jem.20181040","article-title":"Gene therapy targeting SARM1 blocks pathological axon degeneration in mice","volume":"216","author":"Geisler","year":"2019","journal-title":"J Exp Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108588","article-title":"Small molecule SARM1 inhibitors recapitulate the SARM1-\/- phenotype and allow recovery of a metastable pool of axons fated to degenerate","volume":"34","author":"Hughes","year":"2021","journal-title":"Cell Rep"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110108","article-title":"Sarm1 haploinsufficiency or low expression levels after antisense oligonucleotides delay programmed axon degeneration","volume":"37","author":"Gould","year":"2021","journal-title":"Cell Rep"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2005.09.006","article-title":"Spliceosome-mediated RNA trans-splicing","volume":"12","author":"Yang","year":"2005","journal-title":"Mol Ther"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2021.10.019","article-title":"Autosomal dominant optic atrophy: A novel treatment for OPA1 splice defects using U1 snRNA adaption","volume":"26","author":"J\u00fcschke","year":"2021","journal-title":"Mol Ther Nucleic Acids"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddac128","article-title":"Modelling autosomal dominant optic atrophy associated with OPA1 variants in iPSC-derived retinal ganglion cells","volume":"31","author":"Sladen","year":"2022","journal-title":"Hum Mol Genet"},{"key":"B72","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.stemcr.2023.11.004","article-title":"Human retinal organoids with an OPA1 mutation are defective in retinal ganglion cell differentiation and function","volume":"19","author":"Lei","year":"2024","journal-title":"Stem Cell Rep"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01387","article-title":"CRISPR gene therapy: applications, limitations, and implications for the future","volume":"10","author":"Uddin","year":"2020","journal-title":"Front Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbab014","article-title":"Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics","volume":"4","author":"Liu","year":"2021","journal-title":"Precis Clin Med"}],"container-title":["Frontiers in Ophthalmology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fopht.2025.1688232\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:22:31Z","timestamp":1762320151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fopht.2025.1688232\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":74,"alternative-id":["10.3389\/fopht.2025.1688232"],"URL":"https:\/\/doi.org\/10.3389\/fopht.2025.1688232","relation":{},"ISSN":["2674-0826"],"issn-type":[{"value":"2674-0826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"article-number":"1688232"}}